| Literature DB >> 33500618 |
Zhao Li1,2, Iftikhar Ali1,3, Jiying Qiu4, Huanzhu Zhao1, Wenya Ma1,2, Aiying Bai5, Daijie Wang1, Jingchao Li1.
Abstract
BACKGROUND: Dihydromyricetin (DMY), a natural flavonoid, has reportedly antibacterial, antioxidant, anticancer and other properties. In the present study, DMY was used as a reducing agent and stabilizer to synthesize silver nanoparticles (AgNPs), and the optimal conditions for its synthesis were studied. The DMY-AgNPs were investigated for their DPPH scavenging properties and their potential against human pathogenic and food-borne bacteria viz. Escherichia coli (E. coli), and Salmonella. In addition, DMY-AgNPs also showed excellent inhibitory effects on cancer Hela, HepG2 and MDA-MB-231 cell lines.Entities:
Keywords: DMY-AgNO3-NPs; DPPH; Escherichia coli; Hela; HepG2; MDA-MB-231; Salmonella; green approach; natural flavonoid
Mesh:
Substances:
Year: 2021 PMID: 33500618 PMCID: PMC7826068 DOI: 10.2147/IJN.S283677
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1(A) DMY. (B) DMY after addition of alkali. (C) DMY is initially mixed with AgNO3. (D) DMY reacted with AgNO3 for 3 h.
Figure 2(A) UV-Vis spectra of AgNPs synthesized by DMY at different AgNO3 concentrations. (B) Silver ion conversion rate of AgNPs synthesized by DMY at different AgNO3 concentrations. (C) UV-Vis spectra of AgNPs synthesized by DMY at different pH. (D) Silver ion conversion rate of AgNPs synthesized by DMY at different pH. (E) UV-Vis spectra of AgNPs synthesized by DMY at different temperatures. (F) silver ion conversion rate of AgNPs synthesized by DMY at different temperatures.
Figure 3(A) TEM image of DMY-mediated AgNPs. (B) SEM image of DMY-mediated AgNPs. (C) FTIR image of DMY-mediated AgNPs. (D) XRD pattern of DMY-mediated AgNPs. (E) XPS pattern of AgNPs synthesized by DMY (F) DLS pattern of DMY-mediated AgNPs.
Figure 4Comparison of free radical DPPH scavenging rate among DMY-AgNPs and DMY and BHT.
Figure 5Number of viable bacteria of culture medium. (A) E. coli. (B) E. coli treated with 0.1 mg/mL DMY. (C) E. coli treated with 0.1 mg/mL DMY-AgNPs. (D) E. coli treated with 0.1 mg/mL tetracycline. (E) Salmonella. (F) Salmonella treated with 0.1 mg/mL DMY. (G) Salmonella treated with 0.1 mg/mL DMY-AgNPs. (H) Salmonella treated with 0.1 mg/mL tetracycline.
Figure 6The inhibition rate curves of different samples to bacteria. (A) E. coli. (B) Salmonella.
Figure 7SEM images of bacterial morphology. (A) E. coli. (B) E. coli with DMY. (C) E. coli with DMY-AgNPs. (D) E. coli with tetracycline. (E) Salmonella. (F) Salmonella with DMY. (G) Salmonella with DMY-AgNPs. (H) Salmonella with tetracycline.
Figure 8The inhibition rate curves of AgNPs to different cancer cell lines. (A) Hela. (B) HepG2. (C) MDA-MB-231.